Study: NCT02291289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Description: 500 mg/m\^2 via IV infusion on Day 1 of every 2-week cycle

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX induction regimen
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX induction regimen
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX induction regimen
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Intervention type: DRUG
Group type: OTHER
Intervention: FOLFOX induction regimen
Description: Administered per the Investigator's discretion in accordance with locally approved prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoropyrimidine (5-FU/LV or capecitabine)
Description: Per Investigator's discretion: 5-FU 1600-2400 mg/m\^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m\^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m\^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.